Health Benefit Package Revision Is an Art as Much as a Science – Lessons Learned on the Organization of the Appraisal Phase

Document Type : Editorial

Authors

1 Radboud University Medical Center, Nijmegen, The Netherlands

2 Ministry of Health and Medical Education, Tehran, Iran

3 World Health Organisation (WHO), Geneva, Switzerland

4 Aga Khan University, Karachi, Pakistan

5 London School of Hygiene & Tropical Medicine, London, UK

6 University of Rwanda, Kigali, Rwanda

7 Ministry of Health, Astana, Kyrgyzstan

Abstract

Many low- and middle-income countries are designing or revising their health benefit packages (HBPs), with appraisal—prioritizing services for reimbursement—being a critical phase. This occurs in a complex landscape of multiple criteria, multiple stakeholders, limited evidence, budget constraints, and tight timelines, varying across countries. Existing guidance documents do not fully address these complexities, requiring analysts to balance methodological rigor with practical constraints. This editorial highlights four key themes in organizing appraisal: decision-making structures, trade-offs between criteria, final recommendations, and the use of cost-effectiveness evidence, thresholds, and budgets. These emerged as central challenges in HBP revisions in Iran, Kyrgyzstan, Liberia, Pakistan, and Rwanda. We emphasize cross-country learning to address these challenges pragmatically, recognizing that high-quality, legitimate appraisal is as much an art as a science. More detailed documentation of appraisal processes is needed to refine HBP revision guidelines and strengthen priority-setting in health systems. 

Keywords


  1. Glassman A, Giedion U, Smith PC. What's In, What's Out: Designing Benefits for Universal Health Coverage. Washington, DC: Brookings Institution Press, Center for Global Development; 2017.
  2. Alwan A, Yamey G, Soucat A. Essential packages of health services in low-income and lower-middle-income countries: what have we learnt? BMJ Glob Health. 2023;8(Suppl 1):e010724. doi:1136/bmjgh-2022-010724
  3. Oortwijn W, Jansen M, Baltussen R. Evidence-Informed Deliberative Process: A Practical Guide for HTA Bodies for Legitimate Benefit Package Design. Nijmegen: Radboud University Medical Center; 2021. https://www.radboudumc.nl/global-health-priorities.
  4. Baltussen R, Jansen M, Akhtar SS, et al. The use of evidence-informed deliberative processes for designing the essential package of health services in Pakistan. Int J Health Policy Manag. 2024;13:8004. doi:34172/ijhpm.2023.8004
  5. Nouhi M, Baltussen R, Razavi SS, et al. The use of evidence-informed deliberative processes for health insurance benefit package revision in Iran. Int J Health Policy Manag. 2022;11(11):2719-2726. doi:34172/ijhpm.2022.6485
  6. World Health Organization (WHO). WHO Consultative Group on Equity and Universal Health Coverage. Making Fair Choices on the Path to UHC. Geneva: WHO; 2016.
  7. Bertram M, Dhaene G, Tan-Torres Edejer T. Institutionalizing Health Technology Assessment Mechanisms: A How to Guide. World Health Organization; 2021. https://iris.who.int/handle/10665/340722.
  8. The HTA Toolkit of the international Decision Support Initiative (iDSI), 2018. http://www.idsihealth.org/HTATOOLKIT/.
  9. Alwan A, Jallah W, Baltussen R, et al. Designing an evidence-informed package of essential health services for universal health coverage: lessons learnt and challenges to implementation in Liberia. BMJ Glob Health. 2024;9(6):e014904. doi:1136/bmjgh-2023-014904
  10. Baltussen R, Mwalim O, Blanchet K, et al. Decision-making processes for essential packages of health services: experience from six countries. BMJ Glob Health. 2023;8(Suppl 1):e010704. doi:1136/bmjgh-2022-010704
  11. Baltussen R, Marsh K, Thokala P, et al. Multicriteria decision analysis to support health technology assessment agencies: benefits, limitations, and the way forward. Value Health. 2019;22(11):1283-1288. doi:1016/j.jval.2019.06.014
  12. Thokala P, Devlin N, Marsh K, et al. Multiple criteria decision analysis for health care decision making--an introduction: report 1 of the ISPOR MCDA Emerging Good Practices Task Force. Value Health. 2016;19(1):1-13. doi:1016/j.jval.2015.12.003
  13. Marsh K, Ijzerman MJ, Thokala P, et al. Multiple criteria decision analysis for health care decision making--emerging good practices: report 2 of the ISPOR MCDA Emerging Good Practices Task Force. Value Health. 2016;19(2):125-137. doi:1016/j.jval.2015.12.016
  14. National Institute for Health and Care Excellence (NICE). Guide to the Methods of Technology Appraisal. London, UK: NICE; 2013.
  15. Zorginstituut Nederland (Netherlands Health Care Institute). Kosteneffectiviteit in de Praktijk (Cost-Effectiveness Analysis in Practice). Diemen: Zorginstituut Nederland; 2015.
  16. Butani D, Faradiba D, Dabak SV, et al. Expanding access to high-cost medicines under the universal health coverage scheme in Thailand: review of current practices and recommendations. J Pharm Policy Pract. 2023;16(1):138. doi:1186/s40545-023-00643-z
  17. Eregata GT, Hailu A, Geletu ZA, et al. Revision of the Ethiopian essential health service package: an explication of the process and methods used. Health Syst Reform. 2020;6(1):e1829313. doi:1080/23288604.2020.1829313
  18. Torres-Rueda S, Vassall A, Zaidi R, et al. The use of evidence to design an essential package of health services in Pakistan: a review and analysis of prioritisation decisions at different stages of the appraisal process. Int J Health Policy Manag. 2024;13:8043. doi:34172/ijhpm.2024.8043
  19. Santos AS, Guerra-Junior AA, Godman B, Morton A, Ruas CM. Cost-effectiveness thresholds: methods for setting and examples from around the world. Expert Rev Pharmacoecon Outcomes Res. 2018;18(3):277-288. doi:1080/14737167.2018.1443810

Articles in Press, Corrected Proof
Available Online from 16 February 2025
  • Receive Date: 23 September 2024
  • Revise Date: 05 February 2025
  • Accept Date: 11 February 2025
  • First Publish Date: 16 February 2025